The Journal of the Association of Physicians of India · 2018
Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gautam Ashish, Agrawal Prabhat Kumar, Doneria Jitender, Nigam Ashwini
Аннотация
INTRODUCTION: Canagliflozin, a second line OHA is well known to reduce weight. Patients of type 2 diabetes with non-alcoholic fatty liver disease (NAFLD) frequently have abnormal liver functions. We evaluated role of canagliflozin in reducing weight and improving liver function tests (LFT) in type 2 diabetes with NAFLD.
AIMS: Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease.
METHODS: We selected type 2 diabetes patients who were having comorbid NAFLD with abnormal LFT. Subjects were prescribed canagliflozin in dose of 100mg/ day for 6 months. Dose adjustments of other drugs (oral hypoglycemics agents and insulins) was done to monitor glycemic target. Effects of canagliflozin was observed on LFT, vitals and HbA1c. It was an observational study. Subjects who developed major side effects were excluded and managed.
RESULTS: One subject was lost to follow up during study and 31 completed the study successfully. Average HbA1c and weight differences were -0·46% and -1·86% respectively. Average ALT reduction was 36 U/L; t= -9·153623, p is < 0·00001. Average AST reduction was 19·0 U/L; t= -8·153600; p is <0·00001. Average GGT reduction was 5·87 U/L; t= -3·286677, p=0·002588. Average ALP reduction was 1·68 U/L; t= -1·295661. p=0·204973. Serum Bilirubin was elevated by 0·04%; t=0·912, p=0·368. With 0·46% reduction in HbA1c there is 37·5% reduction in ALT levels (R=0·1424) and with 1·86% weight reduction there is 37·5% ALT reduction (R=0·3448).
CONCLUSIONS: Canagliflozin controls HbA1c and reduce weight in type 2 diabetes. It also significantly improves LFT in co-morbid NAFLD.
AIMS: Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease.
METHODS: We selected type 2 diabetes patients who were having comorbid NAFLD with abnormal LFT. Subjects were prescribed canagliflozin in dose of 100mg/ day for 6 months. Dose adjustments of other drugs (oral hypoglycemics agents and insulins) was done to monitor glycemic target. Effects of canagliflozin was observed on LFT, vitals and HbA1c. It was an observational study. Subjects who developed major side effects were excluded and managed.
RESULTS: One subject was lost to follow up during study and 31 completed the study successfully. Average HbA1c and weight differences were -0·46% and -1·86% respectively. Average ALT reduction was 36 U/L; t= -9·153623, p is < 0·00001. Average AST reduction was 19·0 U/L; t= -8·153600; p is <0·00001. Average GGT reduction was 5·87 U/L; t= -3·286677, p=0·002588. Average ALP reduction was 1·68 U/L; t= -1·295661. p=0·204973. Serum Bilirubin was elevated by 0·04%; t=0·912, p=0·368. With 0·46% reduction in HbA1c there is 37·5% reduction in ALT levels (R=0·1424) and with 1·86% weight reduction there is 37·5% ALT reduction (R=0·3448).
CONCLUSIONS: Canagliflozin controls HbA1c and reduce weight in type 2 diabetes. It also significantly improves LFT in co-morbid NAFLD.